证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2023-005 投资者关系活 ■特定对象调研 □分析师会议 □媒体采访 动类别 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（分析师电话会议） 参与单位名称 国泰基金：邓时锋；盈联资本：应振洲；惠正私募：訾力强；嘉 及人员姓名 实基金：李慧；东方红：马庆华；中欧基金：赵磊；海通证券： 彭聘；兴业证券：东楠；广发基金：王瑞冬；奥博资本：星璇； 汇添富：谢杰；德邦证券：吴沛柯；国君证券：谈嘉程。 时间 2023 年 6 月 16 日 16:00-17:30 地点 浙江省台州市仙居县白塔镇迎仙路 2 号二楼会议室 上市公司接待 董事长/总经理：胡赓熙；副总经理/董事会秘书：管祯玮；市场 人员姓名 部副经理：季龙。 1、 公司产品"黄花蒿花粉变应原舌下滴剂"和"粉尘螨滴剂" 使用时间和见效时间是否一致？ 粉尘螨是全年性过敏原，黄花蒿花粉是季节性过敏原（夏秋 季花粉），所以评估两个产品疗效需要的时间是不同的。"粉尘螨 滴剂"在使用过程中会逐渐见到疗效，而"黄花蒿花粉变应原舌 投资者关系活 下滴剂"的疗效需 ...

证券代码：300357 证券简称：我武生物 编号：2023-004 投资者关系活 □特定对象调研 □分析师会议 □媒体采访 动类别 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（分析师电话会议） 通过全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年 参与单位名称 及人员姓名 度业绩说明会的投资者 时间 2023 年 5 月 6 日 9:30-11:00 地点 网上业绩说明会（全景网"投资者关系互动平台"） 上市公司接待 董事长/总经理：胡赓熙；独立董事：张飞达（ZHANG FEIDA）； 人员姓名 副总经理/董事会秘书：管祯玮；财务负责人：王国其 提问 1：1、从黄花蒿花粉变应原舌下滴剂库存量看，业务开 展及销售增长是否严重低于公司预期？除了加大学术推广及销 售力度外，公司是否会回顾一下黄花蒿花粉变应原舌下滴剂的定 价策略？2、公司前 5 大销售客户销售金额占比 45.34%，是否存 在经营风险？ 答：投资者您好！"黄花蒿花粉变应原舌下滴剂"目前仍处 投资者关系活 于早期推广销售阶段，该品种的定价是综合考虑了目前市场竞争 动主要内容介 环境、未来通胀等诸多因素。公司前 ...

Revenue and Profitability - The company's total revenue for the first quarter was approximately ¥197.59 million, with a net profit attributable to shareholders of ¥91.74 million[41]. - In the second quarter, revenue reached approximately ¥191.32 million, with a net profit attributable to shareholders of ¥89.35 million[41]. - The third quarter saw revenue increase to approximately ¥311.28 million, with a net profit attributable to shareholders of ¥146.13 million[41]. - The fourth quarter's revenue was approximately ¥195.84 million, with a net profit attributable to shareholders of ¥21.56 million[41]. - The net profit after deducting non-recurring gains and losses for the entire year was approximately ¥76.73 million in Q1, ¥77.30 million in Q2, ¥139.04 million in Q3, and ¥21.49 million in Q4[41]. - The company's operating revenue for 2022 was ¥896,016,141.32, representing a 10.94% increase compared to ¥807,691,606.00 in 2021[59]. - The net profit attributable to shareholders for 2022 was ¥348,773,471.01, a 3.19% increase from ¥337,991,284.82 in 2021[59]. - The company's total comprehensive income for the year was approximately CNY 335.75 million, a decrease from CNY 352.23 million in the previous year, reflecting a decline of about 4.2%[75]. - Basic and diluted earnings per share increased to CNY 0.6661 from CNY 0.6455, representing a growth of approximately 3.5%[75]. Product Development and Innovation - The company is focusing on the development of natural medicines to combat antibiotic-resistant bacteria, indicating a strategic shift towards innovative drug discovery[51]. - The company is actively expanding its research and development capabilities in the field of natural medicines, which is expected to yield promising market prospects[52]. - The company completed the III phase clinical trial for the "Artemisia annua pollen sublingual drops" for children, which is currently in the CDE technical review stage[96]. - The company has initiated preclinical research for a second stem cell therapy drug aimed at treating osteoarthritis[98]. - The company’s first stem cell therapy drug for osteoporosis has passed quality review and is under submission to the National Health Commission[98]. - The company aims to enter new major medical product fields, including stem cell therapy and natural medicines, targeting the formation of new product clusters in 2-3 therapeutic areas over the next decade[161]. - Ongoing clinical trials include the III phase for "Pollen Extract Injection" and I phase for "Dermatitis Diagnostic Patch," with preclinical research on stem cell therapy products also in progress[164]. Market Position and Strategy - The company maintains a leading position in the domestic market for sublingual immunotherapy products, with its "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops" being the only approved products[50]. - The biopharmaceutical industry in China is experiencing rapid growth, driven by increasing healthcare demands and government support, which presents significant opportunities for the company[47]. - The company is adapting to market changes by enhancing hospital coverage and academic marketing while controlling costs[6]. - The company is focusing on academic marketing strategies to increase product promotion and market penetration[90]. - The company plans to enhance its sales network, particularly in northern China, to better align with regional economic development and market demand[164]. Financial Management and Investments - The company reported a cash flow from operating activities of ¥360,279,064.78, a slight decrease of 0.08% compared to ¥360,575,120.69 in 2021[59]. - The company has established a self-sufficient stem cell culture system and developed a series of core technologies in the stem cell field, indicating a focus on innovation and market expansion[73]. - The company reported cash inflows from investment activities of CNY 566.86 million, down from CNY 754.99 million, reflecting a decrease of approximately 25%[77]. - The net cash flow from investment activities was negative at CNY -118.19 million, an improvement from CNY -212.31 million in the previous year[77]. - The company has a total of 65.81 million yuan in surplus raised funds, primarily due to strict procurement controls and cost reductions during project implementation[175]. - The company terminated the "Marketing Network Expansion and Information Technology Construction Project," resulting in a permanent allocation of 28.88 million yuan in surplus funds to working capital[175]. Risk Management and Regulatory Compliance - The company faces risks related to concentrated main products, as the sales of "Dust Mite Drops" largely determine overall profitability[28]. - The company acknowledges the risk of industry policy changes and plans to actively implement measures to control operational risks[24]. - The company is facing regulatory challenges due to tightening drug management laws, which may impact the drug registration process and overall market competitiveness[167]. - The company has established a governance structure that complies with relevant laws and regulations, enhancing its internal control systems[172]. - The company has implemented measures to monitor industry policy changes to mitigate operational risks[195]. Research and Development Expenditure - Total R&D investment for the year was ¥116,665,722.78, accounting for 13.02% of operating revenue[93]. - The company is actively expanding its R&D efforts into stem cells and natural medicines, with specific investments of ¥56,782,780.57 and ¥12,981,322.98 respectively[93]. - R&D expenses rose by 20.58% to ¥106,019,343.61, indicating a significant investment in innovation[122]. - The capitalized R&D expenditure accounted for 9.13% of total R&D investment, down from 13.82% in the previous year[143]. Corporate Governance - The company completed the board of directors' re-election on December 28, 2022, with the new board serving a three-year term[192]. - The company has established a sound corporate governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring effective oversight and compliance[200]. - The company has a supervisory board consisting of three members, including one employee representative, ensuring compliance with legal requirements[192]. - The company has not provided guarantees for its controlling shareholders, maintaining financial independence[200]. - The company ensures that all shareholders, especially minority shareholders, have equal rights and opportunities to participate in meetings[200].

Financial Performance - The company's operating revenue for Q1 2023 was ¥183,139,637.81, a decrease of 7.31% compared to the same period last year[8] - Net profit attributable to shareholders was ¥70,478,103.64, down 23.17% year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥67,924,569.47, a decrease of 11.48% compared to the previous year[8] - The company reported a total profit of ¥74,695,305.79, compared to ¥106,121,775.74 in the previous year, representing a decrease of 29.6%[33] - The net profit margin decreased to 36.2% from 46.4% year-over-year, highlighting a significant drop in profitability[33] - Basic and diluted earnings per share were both 0.1346, down from 0.1752 in the previous period[36] Cash Flow - The net cash flow from operating activities increased by 50.95% to ¥83,916,819.04 compared to the same period last year[8] - Cash inflow from operating activities totaled 233,270,208.98, slightly up from 229,210,561.85[36] - Net cash flow from operating activities increased to 83,916,819.04 from 55,592,478.71, representing a significant improvement[36] - Cash inflow from investment activities was 169,277,857.45, compared to 71,817,750.95 in the previous period[37] - Net cash flow from investment activities was -25,985,064.22, an improvement from -36,137,641.70[37] - Cash inflow from financing activities was 20,000,000.00, with net cash flow from financing activities at 18,155,668.39, compared to -1,029,911.15 previously[37] - The net increase in cash and cash equivalents was ¥57,660,630.02, reflecting a 313.03% increase compared to the same period last year[13] - The ending balance of cash and cash equivalents reached 486,872,767.67, compared to 298,128,769.36 at the end of the previous period[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,257,726,099.79, an increase of 2.72% from the end of the previous year[8] - The company's equity attributable to shareholders increased by 3.56% to ¥2,050,012,917.00 compared to the end of the previous year[8] - The company's total assets increased to ¥2,257,726,099.79 from ¥2,197,788,958.32, reflecting growth in financial stability[33] - The company's total liabilities decreased to RMB 163,682,765.73 from RMB 170,760,022.93, indicating a reduction of about 4.1%[24] - The company reported a decrease in accounts payable from RMB 7,682,719.29 to RMB 5,373,862.77, a decline of approximately 30.1%[24] - The company’s non-current liabilities increased slightly to RMB 69,759,246.60 from RMB 68,008,569.94, reflecting a growth of about 2.6%[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,133, with the largest shareholder holding 38.86% of the shares[14] - The total equity attributable to shareholders increased to ¥2,050,012,917.00 from ¥1,979,540,771.28, showing a growth of 3.5%[33] Other Income and Investments - The company reported a significant decrease in other income, down 94.46% to ¥12,999,996.60, primarily due to reduced government subsidies related to daily operations[13] - The company reported an investment income of ¥2,468,267.68, significantly up from ¥674,438.30 in the previous year, indicating improved investment performance[33] Clinical Trials and Research - The company received a formal acceptance notice from the National Medical Products Administration for its clinical trial application of "Yanqumei Point Injection" in February 2023[21] - The company initiated a clinical study for its "Dermatitis Diagnostic Patch 01" with the first subject enrolled in February 2023[21] Inventory and Current Assets - Total current assets decreased to RMB 1,464,063,377.89 from RMB 1,477,132,637.58, indicating a decline of about 0.9%[22] - The company's inventory increased to RMB 50,605,440.56 from RMB 48,410,643.38, representing a growth of approximately 4.9%[22] Audit Information - The company did not undergo an audit for the first quarter report[38]

出席本次年度网上业绩说明会的人员有：公司董事长兼总经理胡赓熙先生、 独立董事张飞达（ZHANG FEIDA）先生、副总经理兼董事会秘书管祯玮先生、 财务负责人王国其先生。 证券代码：300357 证券简称：我武生物 公告编号：2023-019 号 浙江我武生物科技股份有限公司 关于举行 2022 年度网上业绩说明会并征集相关问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江我武生物科技股份有限公司（以下简称"公司"）2022年年度报告于 2023年4月21日在深圳证券交易所网站和符合中国证监会规定条件的媒体上披 露，为让广大投资者进一步了解公司2022年年度报告及经营情况，公司将于2023 年5月6日9:30-11:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将 采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 浙江我武生物科技股份有限公司董事会 2023年4月21日 2 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公 ...